Citations

Mayo Clinic

Clear

13609 citation(s) found for "_, _".

Liars, Damn Liars, and Propensity Scores
Nuttall, Gregory A. , Houle, Timothy T.

Anesthesiology | March 4, 2009 | Volume: 108 | Issue: 1 | Pages: 3-4

10.1097/01.anes.0000296718.35703.20 | PMID 18156873 Get It

Evaluation of a New Mechanical Pressure Tester for Barrier Fabrics
McCullough, EA, Johnson, P.V.

Performance of Protective Clothing: Sixth Volume | March 4, 2009 | Volume: No volume available | Issue: No issue available | Pages: 37-46

10.1520/stp19891s Get It

ASTM F23.40.04, Draft Test Method for the Resistance of Materials Used in Protective Clothing to Penetration by Synthetic Blood Using a Mechanical Pressure Technique, was evaluated and compared to three other barrier test methods that apply hydrostatic pressure to the liquid and fabric. The new instrument applies continuous mechanical pressure to the fabric and synthetic blood until penetration is visible, and the penetration pressure level is recorded. The barrier properties of 14 different surgical gown materials and control fabrics were measured using the new method and ASTM F 1670 and F 1671 and AATCC 127. Surgical gown materials reinforced with films, coatings, or membranes passed ASTM F 1670 and F 1671 and reached the highest pressure level attainable on the AATCC 127 and ASTM F23.40.04 tests. Single-layer and fabric reinforced gowns exhibited varying degrees of liquid resistance. The new method simulates the high mechanical pressures of short duration that occur during surgery. It deserves consideration as a standard.
Clinical use of proton-pump inhibitors but not H 2 -blockers or antacid/alginates raises the serum levels of amidated gastrin-17, pepsinogen I and pepsinogen II in a random adult population
Agréus, Lars , Storskrubb, Tom, Aro, Pertti , Ronkainen, Jukka , Talley, Nicholas J. , Sipponen, P.

Scandinavian Journal of Gastroenterology | March 4, 2009 | Volume: 44 | Issue: 5 | Pages: 564-570

10.1080/00365520902745062 | PMID 19263272 Get It

Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study
Höchster, Howard S. , Weller, Edie, Gascoyne, Randy D. , Gordon, Leo I. , Ryan, Theresa, Zhang, Lijun , Colocci, Natalia, Frankel, Stanley, Horning, Sandra J., Habermann, Thomas M. , Gordon, Leo I

Journal of Clinical Oncology | March 3, 2009 | Volume: 27 | Issue: 10 | Pages: 1607-1614

10.1200/jco.2008.17.1561 | PMID 19255334 Get It

Purpose To determine if maintenance rituximab (MR) after standard chemotherapy improves progression-free survival (PFS) in advanced-stage indolent lymphoma. Patients and Methods Patients with stage III-IV indolent lymphoma with responding or stable disease after cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy were stratified by initial tumor burden, residual disease after CVP (minimal or gross), and histology, and randomly assigned to observation (OBS) or MR 375 mg/m2 once per week for 4 weeks every 6 months for 2 years. PFS was the primary end point. Results Three hundred eleven (282 with follicular lymphoma) evaluable patients who received CVP were randomly assigned to OBS (n = 158) or MR (n = 153). Best response improved in 22% MR versus 7% OBS patients (P = .00006). Toxicity was minimal in both study arms. Three-year PFS after random assignment was 68% MR versus 33% OBS (hazard ratio [HR] = 0.4; P = 4.4 × 10−10 [all patients]) and 64% MR v 33% OBS (HR = 0.4; P = 9.2 × 10−8 [patients with follicular lymphoma]). There was an advantage for MR regardless of Follicular Lymphoma International Prognostic Index score, tumor burden, residual disease, or histology. In multivariate analysis of MR patients, minimal disease after CVP was a favorable prognostic factor. OS at 3 years was 92% MR versus 86% OBS (HR = 0.6; log-rank one-sided P = .05) and, among patients with follicular lymphoma, OS was 91% MR versus 86% (HR = 0.6; log-rank one-sided P = .08). A trend favoring MR was observed among patients with high tumor burden (log-rank one-sided P = .03). Conclusion The E1496 study provides the first phase III data in untreated indolent lymphoma that MR after chemotherapy significantly prolongs PFS.
The Tamoxifen Metabolite, Endoxifen, Is a Potent Antiestrogen that Targets Estrogen Receptor α for Degradation in Breast Cancer Cells
Wu, Xianglin, Hawse, John R. , Subramaniam, Malayannan , Spelsberg, Thomas C., Goetz, Matthew P. , Ingle, James N.

Cancer Research | February 25, 2009 | Volume: 69 | Issue: 5 | Pages: 1722-1727

10.1158/0008-5472.can-08-3933 | PMID 19244106 Get It

Abstract Tamoxifen has been the most important therapeutic agent for the treatment of estrogen receptor (ER)-positive breast cancer for the past three decades. Tamoxifen is extensively metabolized by cytochrome P450 enzymes, and recent in vivo studies have shown that women with genetically impaired cytochrome P450 2D6 have reduced production of endoxifen and a higher risk of breast cancer recurrence. Despite these observations, the contribution of endoxifen to the overall drug effectiveness of tamoxifen remains uncertain. Here, we provide novel evidence that endoxifen is a potent antiestrogen that functions in part by targeting ERα for degradation by the proteasome in breast cancer cells. Additionally, we show that endoxifen blocks ERα transcriptional activity and inhibits estrogen-induced breast cancer cell proliferation even in the presence of tamoxifen, N-desmethyl-tamoxifen, and 4-hydroxytamoxifen. All of the effects of endoxifen are concentration dependent and do not occur at concentrations observed in human CYP2D6 poor metabolizers. These results support the theory that endoxifen is the primary metabolite responsible for the overall effectiveness of tamoxifen in the treatment of ER-positive breast cancer. [Cancer Res 2009;69(5):1722–7]
Lange Q & A: Radiography Examination, 7th ed.
Olejniczak, S

American Journal of Roentgenology | February 22, 2009 | Volume: 192 | Issue: 3 | Pages: W137-W137

10.2214/ajr.08.1989 Get It

Letter by Sengupta et al Regarding Article, “Mechanisms of Preejection and Postejection Velocity Spikes in Left Ventricular Myocardium: Interaction Between Wall Deformation and Valve Events”
Sengupta, Partho P. , Khandheria, Bijoy K. , Bëlohlávek, Marek

Circulation | February 16, 2009 | Volume: 119 | Issue: 6 | Pages: No page available

10.1161/circulationaha.108.811182 | PMID 19221225 Get It

Consistency of Response to Sumatriptan/Naproxen Sodium in a Placebo-Controlled, Crossover Study
Lipton, RB, Dodick, DW, Ju, Adelman, Kaniecki, R. G., Lener, SE, White, J A, Nelsen, AC

Cephalalgia | February 12, 2009 | Volume: 29 | Issue: 8 | Pages: 826-836

10.1111/j.1468-2982.2008.01806.x | PMID 19220307 Get It

Two identical randomized, placebo-controlled, crossover studies were conducted to evaluate consistency of response to sumatriptan/naproxen sodium 85/500 mg (S/NS) over four attacks in adults with migraine. Patients were instructed to treat within 1 h of pain onset while pain was mild. Co-primary end-points were pain-free response at 2 h (2hPF) and 24-h sustained pain-free response (24hSPF) calculated as percentages of all attacks. In Study 1, 570 patients treated 1693 attacks with S/NS and 424 with placebo. In Study 2, 565 patients treated 1678 attacks with S/NS and 422 with placebo. Compared with placebo, S/NS conferred higher 2hPF rates (Study 1: S/NS 52%, placebo 25%; Study 2: S/NS 50%, placebo 20%; both P < 0.001) and higher 24hSPF rates (Study 1: S/NS 37%, placebo 17%; Study 2: S/NS 34%, placebo 12%; both P < 0.001). 2hPF was reported in at least two of the first three S/NS-treated attacks in 55.0% of patients in Study 1 and 52.1% of patients in Study 2. 24hSPF was reported in at least two of the first three S/NS-treated attacks in 35.7% of patients in Study 1 and 32.6% of patients in Study 2. The incidences of any adverse event and of specific adverse events were low and generally similar between S/NS and placebo.
Bladder Cancer–Associated Gene Expression Signatures Identified by Profiling of Exfoliated Urothelia
Rosser, Charles J. , Liu, Li , Villicana, Patrick, McCullers, Molly, Porvasnik, Stacy, Parker, Alexander S. , Goodison, Steve , Sun, Yijun , Young, Paul R.

Cancer Epidemiology, Biomarkers & Prevention | February 10, 2009 | Volume: 18 | Issue: 2 | Pages: 444-453

10.1158/1055-9965.epi-08-1002 | PMID 19190164 Get It

Abstract Bladder cancer is the fifth most commonly diagnosed malignancy in the United States and one of the most prevalent worldwide. It harbors a probability of recurrence of &gt;50%; thus, rigorous, long-term surveillance of patients is advocated. Flexible cystoscopy coupled with voided urine cytology is the primary diagnostic approach, but cystoscopy is an uncomfortable, invasive procedure and the sensitivity of voided urine cytology is poor in all but high-grade tumors. Thus, improvements in noninvasive urinalysis assessment strategies would benefit patients. We applied gene expression microarray analysis to exfoliated urothelia recovered from bladder washes obtained prospectively from 46 patients with subsequently confirmed presence or absence of bladder cancer. Data from microarrays containing 56,000 targets was subjected to a panel of statistical analyses to identify bladder cancer-associated gene signatures. Hierarchical clustering and supervised learning algorithms were used to classify samples on the basis of tumor burden. A differentially expressed geneset of 319 gene probes was associated with the presence of bladder cancer (P &lt; 0.01), and visualization of protein interaction networks revealed vascular endothelial growth factor and angiotensinogen as pivotal factors in tumor cells. Supervised machine learning and a cross-validation approach were used to build a 14-gene molecular classifier that was able to classify patients with and without bladder cancer with an overall accuracy of 76%. Our results show that it is possible to achieve the detection of bladder cancer using molecular signatures present in exfoliated tumor urothelia. Further investigation and validation of the cancer-associated profiles may reveal important biomarkers for the noninvasive detection and surveillance of bladder cancer. (Cancer Epidemiol Biomarkers Prev 2009;18(2):444–53)
Asthma-Related Environmental Fungus, Alternaria , Activates Dendritic Cells and Produces Potent Th2 Adjuvant Activity
Iijima, Koji, Radhakrishnan, Suresh , Mehta, Vinay , Vassallo, Robert , Lawrence, Christopher B. , Cyong, Jong-Chol, Pease, Larry R. , Oguchi, Katsuji, Kita, Hirohito , Kobayashi, Takao , Kita, H , Vassallo, Robert

The Journal of Immunology | February 9, 2009 | Volume: 182 | Issue: 4 | Pages: 2502-2510

10.4049/jimmunol.0802773 | PMID 19201906 Get It

Abstract Asthma is thought to result from dysregulated Th2-like airway inflammatory responses to the environment. Although the etiology of asthma is not fully understood in humans, clinical and epidemiological evidence suggest a potential link between exposure to environmental fungi, such as Alternaria, and development and/or exacerbation of asthma. The goal of this project was to investigate the mechanisms of airway Th2 responses by using Alternaria as a clinically relevant model for environmental exposure. Airway exposure of naive animals to an experimental Ag, OVA, or a common allergen, short ragweed pollen, induced no or minimal immune responses to these Ags. In contrast, mice developed strong Th2-like immune responses when they were exposed to these Ags in the presence of Alternaria extract. Extracts of other fungi, such as Aspergillus and Candida, showed similar Th2 adjuvant effects, albeit not as potently. Alternaria stimulated bone marrow-derived dendritic cells (DCs) to express MHC class II and costimulatory molecules, including OX40 ligand, in vitro. Importantly, Alternaria inhibited IL-12 production by activated DCs, and DCs exposed to Alternaria enhanced Th2 polarization of CD4+ T cells. Furthermore, adoptive airway transfer of DCs, which had been pulsed with OVA in the presence of Alternaria, showed that the recipient mice had enhanced IgE Ab production and Th2-like airway responses to OVA. Thus, the asthma-related environmental fungus Alternaria produces potent Th2-like adjuvant effects in the airways. Such immunogenic properties of certain environmental fungi may explain their strong relationships with human asthma and allergic diseases.